Furthermore, a significant decrease in MCP-1 levels and reduced monocyte adhesion to the vascular endothelium is observed in users of GLP-1 receptor agonists (semaglutide, dulaglutide), which are drugs registered for the treatment of T2DM and obesity, thus suggesting a potential mechanism for reducing cardiovascular risk [97]. The gene discussed is CCL2; the disease is type 2 diabetes mellitus.